Sinofn Health
Sinofn Health
In the current global nutraceutical landscape, the shift from generic manufacturing to specialized ODM (Original Design Manufacturing) is driven by consumer demand for data-backed transparency. SINOFN leverages deep integration with the Chinese Academy of Sciences to transform the supplement supply chain.
SINOFN Health Co., Ltd. is the dedicated supplement OEM manufacturing division of SINOFN Group – a national high-tech enterprise founded in 2012. Backed by the Chinese Academy of Sciences, we bridge the gap between academic R&D and commercial manufacturing.
Founder: Mrs. GuoHong Liu. Her vision was sparked by the clinical necessity for affordable, science-backed PKU foods. Today, this mission drives our dedication to "Profit with Purpose," investing revenues into medical accessibility.
Medical Innovation Director, PhD from Peking University. Expert in metabolic disorder formulations.
R&D Lead, CAS Postdoc. Specialist in bioactive delivery systems and bioavailability.
Formulation Director (Netherlands). EU regulatory specialist in nutraceutical technology.
10+ lines (Softgels, Gummies, Powders). ISO 22000, HACCP, FSSC 22000. 500M+ units annual capacity.
HPLC/GC-MS contaminant screening and microbiological safety testing for rigorous product validation.
Advanced prototyping for tablets, capsules, and liquids with dedicated bioavailability optimization studies.
End-to-end management from raw material storage to BRCGS-certified warehousing and blockchain tracking.
We operate from our advanced manufacturing hubs, with headquarters and trading operations centered in Shanghai to serve our global partners with high-level logistics and regulatory support.
Yes. Our Tianjin R&D center provides pilot-scale prototyping for tablets, capsules, and liquid formulations, allowing brands to test viability before full-scale manufacturing.
Absolutely. We offer tailored manufacturing scopes that scale with your business, from niche supplement launches to high-volume commercial production, supported by our robust intellectual property portfolio (36+ patents).
